Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Aliskiren attenuates proteinuria in mice with lupus nephritis by a blood pressure-independent mechanism.

Yen TH, Yang HY, Yeh YH, Chu PH, Wen CJ, Fu JF, Wang IK, Liang CC, Chang CT, Chen KH, Tian YC, Hung CC, Lin JL, Yang CW.

Lupus. 2013 Feb;22(2):180-9. doi: 10.1177/0961203312471871. Epub 2012 Dec 20.

PMID:
23257405
2.

Aliskiren ameliorates renal inflammation and fibrosis induced by unilateral ureteral obstruction in mice.

Choi DE, Jeong JY, Lim BJ, Chang YK, Na KR, Shin YT, Lee KW.

J Urol. 2011 Aug;186(2):694-701. doi: 10.1016/j.juro.2011.03.122. Epub 2011 Jun 17. Erratum in: J Urol. 2011 Oct;186(4):1560.

PMID:
21683401
3.

Aliskiren reduced renal fibrosis in mice with chronic ischemic kidney injury--beyond the direct renin inhibition.

Sun CY, Cherng WJ, Jian HZ, Hsu HH, Wu IW, Hsu HJ, Wu MS.

Hypertens Res. 2012 Mar;35(3):304-11. doi: 10.1038/hr.2011.181. Epub 2011 Nov 17.

PMID:
22089535
4.

The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy--a randomized cross-over study.

Szeto CC, Kwan BC, Chow KM, Leung CB, Li PK.

PLoS One. 2013 May 10;8(5):e62736. doi: 10.1371/journal.pone.0062736. Print 2013.

5.
6.

Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease.

Moriyama T, Tsuruta Y, Kojima C, Itabashi M, Sugiura H, Takei T, Ogawa T, Uchida K, Tsuchiya K, Nitta K.

Int Urol Nephrol. 2012 Jun;44(3):841-5. doi: 10.1007/s11255-011-9991-0. Epub 2011 May 28.

PMID:
21626132
7.

Effect of aliskiren on proteinuria in non-diabetic chronic kidney disease: a double-blind, crossover, randomised, controlled trial.

Lizakowski S, Tylicki L, Renke M, Rutkowski P, Heleniak Z, Sławińska-Morawska M, Aleksandrowicz E, Łysiak-Szydłowska W, Rutkowski B.

Int Urol Nephrol. 2012 Dec;44(6):1763-70.

8.

Aliskiren add-on therapy effectively reduces proteinuria in chronic kidney disease: an open-label prospective trial.

Wu MT, Tung SC, Hsu KT, Lee CT.

J Renin Angiotensin Aldosterone Syst. 2014 Sep;15(3):271-7. doi: 10.1177/1470320312467560. Epub 2012 Dec 7.

PMID:
23223162
9.

AT1 antagonism and renin inhibition in mice: pivotal role of targeting angiotensin II in chronic kidney disease.

Fraune C, Lange S, Krebs C, Hölzel A, Baucke J, Divac N, Schwedhelm E, Streichert T, Velden J, Garrelds IM, Danser AH, Frenay AR, van Goor H, Jankowski V, Stahl R, Nguyen G, Wenzel UO.

Am J Physiol Renal Physiol. 2012 Oct;303(7):F1037-48. doi: 10.1152/ajprenal.00672.2011. Epub 2012 Jul 11.

10.

Handle region peptide counteracts the beneficial effects of the Renin inhibitor aliskiren in spontaneously hypertensive rats.

van Esch JH, van Veghel R, Garrelds IM, Leijten F, Bouhuizen AM, Danser AH.

Hypertension. 2011 Apr;57(4):852-8. doi: 10.1161/HYPERTENSIONAHA.110.169060. Epub 2011 Feb 14.

11.

Reversibility of the effects of aliskiren in the renal versus systemic circulation.

Schneider MP, Janka R, Ziegler T, Raff U, Ritt M, Ott C, Veelken R, Uder M, Schmieder RE.

Clin J Am Soc Nephrol. 2012 Feb;7(2):258-64. doi: 10.2215/CJN.05870611. Epub 2011 Dec 15.

12.

Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.

Dietz R, Dechend R, Yu CM, Bheda M, Ford J, Prescott MF, Keefe DL.

J Renin Angiotensin Aldosterone Syst. 2008 Sep;9(3):163-75. doi: 10.1177/1470320308096411.

PMID:
18957387
13.

The renin inhibitor aliskiren upregulates pro-angiogenic cells and reduces atherogenesis in mice.

Pöss J, Werner C, Lorenz D, Gensch C, Böhm M, Laufs U.

Basic Res Cardiol. 2010 Nov;105(6):725-35. doi: 10.1007/s00395-010-0120-5. Epub 2010 Sep 21.

PMID:
20857126
14.

Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.

Uresin Y, Taylor AA, Kilo C, Tschöpe D, Santonastaso M, Ibram G, Fang H, Satlin A.

J Renin Angiotensin Aldosterone Syst. 2007 Dec;8(4):190-8. doi: 10.3317/jraas.2007.028.

PMID:
18205098
15.

Effect of direct renin inhibitor monotherapy on proteinuria in overt diabetic nephropathy.

Silaratana S, Sumransurp S, Duangchana S, Tasanarong A.

J Med Assoc Thai. 2012 Jan;95 Suppl 1:S18-23.

PMID:
23964439
16.

Aliskiren combined with losartan in diabetes and nephropathy.

Kamoi K.

N Engl J Med. 2008 Sep 4;359(10):1069; author reply 1069-70. No abstract available.

PMID:
18777611
17.

Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.

Andersen K, Weinberger MH, Constance CM, Ali MA, Jin J, Prescott MF, Keefe DL.

J Renin Angiotensin Aldosterone Syst. 2009 Sep;10(3):157-67. doi: 10.1177/1470320309342407. Epub 2009 Jul 17.

PMID:
19617271
18.

Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions.

Angeli F, Reboldi G, Mazzotta G, Poltronieri C, Garofoli M, Ramundo E, Biadetti A, Verdecchia P.

Curr Drug Saf. 2012 Feb;7(1):76-85. Review.

PMID:
22663961
19.

[Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].

Horký K.

Vnitr Lek. 2010 Feb;56(2):120-6. Review. Czech.

PMID:
20329582
20.

Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.

Chrysant SG, Murray AV, Hoppe UC, Dattani D, Patel S, Hsu H, Zhang J.

Curr Med Res Opin. 2008 Apr;24(4):1039-47. doi: 10.1185/030079908X280581 . Epub 2008 Feb 27.

PMID:
18307835
Items per page

Supplemental Content

Write to the Help Desk